Compounded GLP-1 Medications: What Patients Should Know

The GLP-1 receptor agonist class, which includes semaglutide and tirzepatide, has fundamentally changed the landscape of medical weight management. As demand has outpaced supply of brand-name formulations, compounded versions of these medications have become an increasingly relevant part of the clinical conversation.

This article is written for patients who want to understand what compounded GLP-1 medications are, how they differ from FDA-approved brand-name products, what the current regulatory framework looks like, and how to evaluate quality and safety when working with a provider who prescribes compounded formulations.

A critical distinction at the outset: Compounded GLP-1 medications are not FDA-approved. They are not generic versions of Ozempic, Wegovy, Mounjaro, or Zepbound. They are not bioequivalent to brand-name products. They are custom-prepared formulations made by licensed pharmacies based on clinician-determined patient-specific medical necessity. Understanding this distinction is essential to making an informed decision.

What Compounding Means

Pharmaceutical compounding is the practice of preparing customized medications to meet the specific needs of individual patients. It is one of the oldest practices in pharmacy, predating the modern pharmaceutical manufacturing industry, and it remains a legally recognized and clinically necessary component of healthcare.

Compounding exists because manufactured medications cannot serve every patient. Reasons for compounding include:

• A patient requires a dose, concentration, or delivery form not commercially available
• A patient has an allergy to an inactive ingredient in the manufactured product
• A commercially manufactured drug is in shortage
• A clinician determines that a patient-specific formulation is medically necessary

Compounded medications are prepared by licensed pharmacists in facilities that meet state and federal regulatory standards. They are dispensed pursuant to a valid patient-specific prescription from a licensed prescriber. They are not mass-produced consumer products.

503A vs 503B Pharmacy Distinction

Not all compounding pharmacies operate under the same regulatory framework. Understanding the distinction between 503A and 503B pharmacies is important for patients evaluating the source of their compounded medications.

503A Pharmacies (Traditional Compounding)

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. These pharmacies:

• Compound medications pursuant to individual patient prescriptions
• Are regulated primarily by state boards of pharmacy
• Operate under the supervision of a licensed pharmacist
• Prepare medications for identified, individual patients based on prescriber orders
• Are not required to register with the FDA as outsourcing facilities
• Must compound using ingredients that meet USP (United States Pharmacopeia) or NF (National Formulary) standards

503A compounding is the traditional model, a pharmacist prepares a medication for a specific patient based on a specific prescription.

503B Pharmacies (Outsourcing Facilities)

Section 503B, established by the Drug Quality and Security Act of 2013, created a category of outsourcing facilities that may compound medications without individual patient prescriptions under more stringent federal oversight. These facilities:

• Register with the FDA and are subject to FDA inspection
• Must comply with Current Good Manufacturing Practice (cGMP) requirements
• May prepare and distribute compounded medications in larger quantities
• Must report adverse events to the FDA
• Are subject to more rigorous quality testing and documentation requirements

503B outsourcing facilities operate under a higher level of federal regulatory scrutiny than 503A pharmacies. For patients, this distinction can be a meaningful quality indicator, though it does not change the fundamental regulatory status of the compounded product.

FDA Regulatory Framework as of 2026

The regulatory landscape for compounded GLP-1 medications has evolved significantly. Patients should understand the current framework to make informed decisions.

The Shortage Context

Brand-name GLP-1 medications, including Novo Nordisk's semaglutide products (Ozempic, Wegovy) and Eli Lilly's tirzepatide products (Mounjaro, Zepbound), have experienced extended periods of shortage since their widespread adoption. During periods of FDA-recognized drug shortage, compounding pharmacies have had broader legal latitude to compound copies of commercially available drugs.

The "Essentially a Copy" Rule

Under federal law, compounding pharmacies are generally prohibited from compounding medications that are "essentially a copy" of a commercially available drug. This rule exists to prevent compounding from functioning as an end-run around the FDA drug approval process.

However, exceptions exist during drug shortages. When the FDA lists a drug on its shortage list, compounding pharmacies may compound copies of that drug to address patient access needs.

April 2026 Enforcement Actions

In April 2026, the FDA took enforcement actions related to the "essentially a copy" provisions as they apply to compounded semaglutide and tirzepatide products. These actions reflected the agency's position on the boundaries of permissible compounding as shortage conditions evolved.

The regulatory environment continues to develop. Patients should understand that:

• The legality of compounding specific GLP-1 formulations depends on current shortage status and regulatory guidance
• Provider and pharmacy compliance with current FDA positions is the patient's best protection
• Regulatory changes may affect the availability of compounded formulations over time

This is an area where working with a knowledgeable provider and a compliant pharmacy matters. Clinics that operate without awareness of, or in disregard for, current regulatory requirements expose patients to legal and safety risk.

How Compounded GLP-1 Differs from Brand-Name

It is essential that patients understand the differences between compounded and brand-name GLP-1 medications. These are not interchangeable products.

Not FDA-Approved

Brand-name medications like Ozempic (semaglutide) and Mounjaro (tirzepatide) have undergone extensive clinical trials, Phase I through Phase III, demonstrating safety, efficacy, and manufacturing consistency. They hold FDA approval for specific indications.

Compounded versions of these medications have not undergone this approval process. They have not been evaluated by the FDA for safety, efficacy, or bioequivalence. This does not mean they are inherently unsafe, but it means they carry a different, and less characterized, risk profile.

Not Bioequivalent

Bioequivalence is a specific regulatory standard demonstrating that two formulations deliver the same active ingredient at the same rate and extent to the site of action. Compounded medications have not been tested for bioequivalence to brand-name products. Differences in formulation, concentration, inactive ingredients, and preparation methods may result in different pharmacokinetic profiles.

Different Formulation and Preparation

Brand-name GLP-1 medications are manufactured under tightly controlled cGMP conditions in FDA-inspected facilities with batch-level quality testing and consistency requirements. Compounded medications, while prepared by licensed pharmacists using USP-grade ingredients, are produced under different conditions with different quality assurance standards, particularly in the 503A setting.

Different Inactive Ingredients

The inactive ingredients (excipients) in compounded formulations may differ from brand-name products. These differences can affect stability, absorption, tolerability, and storage requirements.

Why Physicians May Prescribe Compounded Formulations

Given the differences outlined above, it is reasonable to ask why a physician would prescribe a compounded GLP-1 medication. There are several clinically valid reasons:

Patient-Specific Medical Necessity

A physician may determine that a compounded formulation is medically necessary for a specific patient, for example, when a patient requires a dose not commercially available, has an allergy to an excipient in the brand-name product, or cannot tolerate the standard formulation.

Access During Shortage

When brand-name medications are unavailable due to manufacturer supply limitations, compounded alternatives may provide patient access to therapy that would otherwise be inaccessible. Extended GLP-1 shortages have made this a common clinical scenario.

Cost Considerations

Brand-name GLP-1 medications carry significant retail costs, often exceeding $1,000 per month without insurance coverage. Many patients do not have insurance coverage for weight management indications. Compounded formulations are typically available at a lower cost, which may make therapy accessible to patients who would otherwise be unable to afford treatment.

Dosing Flexibility

Compounded formulations allow for dose customization that may not be available with manufactured products, specific concentrations, titration increments, or combination formulations tailored to individual patient needs.

In all cases, the prescribing decision should be based on a clinician's evaluation of the individual patient, documented clinical rationale, and informed consent that clearly communicates the regulatory status and risk profile of the compounded product.

Quality Indicators Patients Should Look For

Not all compounded GLP-1 products are created equal. Patients should evaluate the quality of the pharmacy and the product before starting treatment. Key indicators include:

Certificate of Analysis (COA)

A reputable compounding pharmacy should provide, or make available upon request, a Certificate of Analysis for each batch of compounded medication. The COA documents:

• Active ingredient identity and potency testing
• Sterility testing results
• Endotoxin testing (for injectable formulations)
• pH and particulate testing
• Beyond-use dating substantiation

If a pharmacy cannot or will not provide a COA, that is a significant concern.

Sterility Testing

Injectable medications must be sterile. Compounding pharmacies preparing sterile products should follow USP <797> standards (or the applicable current revision) for sterile compounding. Ask your provider whether their pharmacy partner conducts batch-level sterility testing.

Licensed and Inspected Pharmacy

The compounding pharmacy should be licensed in the state where it operates and, if a 503B facility, registered with the FDA. State board of pharmacy records and FDA inspection reports for 503B facilities are generally available as public records.

Physician Oversight of Prescribing

A valid prescription from a licensed prescriber, based on a clinical evaluation, is a legal requirement for compounded medications. Providers who dispense compounded GLP-1 medications without conducting a medical evaluation, no health history, no contraindication screening, no clinical assessment, are operating outside the bounds of responsible practice.

Proper Storage and Handling

Compounded GLP-1 medications typically require refrigeration. Your provider should communicate storage requirements clearly and ship medications with appropriate cold-chain packaging.

Red Flags to Avoid

The growth of the compounded GLP-1 market has attracted providers and distributors that do not meet basic standards of quality or compliance. Patients should be cautious of the following:

"Same as Ozempic" or equivalence claims. Any provider or pharmacy that claims their compounded product is "the same as," "equivalent to," or "identical to" a brand-name medication is making a claim that is not supported and potentially violates FDA regulations. Compounded products are not the same as FDA-approved products.

No physician evaluation. If you can obtain a compounded GLP-1 medication without a medical evaluation, without a prescriber reviewing your health history, current medications, and contraindications, the source is not operating responsibly.

Unlicensed or unverifiable pharmacy sources. If you cannot verify the pharmacy's licensure, cannot obtain a COA, or cannot confirm the facility's regulatory status, do not use the product.

Unrealistic pricing. Extremely low prices may indicate cost-cutting on quality testing, ingredient sourcing, or regulatory compliance. Quality compounding has real costs.

No follow-up or monitoring. GLP-1 medications require clinical monitoring, particularly during dose titration. Providers who dispense medication without follow-up plans are not providing adequate care.

Direct-to-consumer models without prescriber involvement. Compounded medications require a valid prescription. Models that bypass the prescriber-patient relationship entirely are not compliant with pharmacy law.

The Role of Physician Oversight

This is the through-line that connects every quality and safety consideration in this article: physician oversight is not optional, it is the foundation of safe compounded medication use.

A qualified physician:

• Evaluates whether GLP-1 therapy is clinically appropriate for the individual patient
• Screens for contraindications (history of medullary thyroid carcinoma, MEN2 syndrome, pancreatitis, severe gastroparesis)
• Determines the appropriate starting dose and titration schedule
• Provides informed consent that clearly explains the compounded product's regulatory status
• Monitors for side effects and therapeutic response
• Manages drug interactions and co-existing conditions
• Adjusts or discontinues therapy based on clinical response

At Bloom Metabolics, compounded GLP-1 protocols are prescribed under the supervision of Dr. Michael Napolitano, MD, with clinical monitoring at scheduled intervals throughout treatment. Every patient receives a medical evaluation before a prescription is written, and ongoing support is built into the program.

For more on GLP-1 medications generally, see our guides on what GLP-1 medications are, semaglutide vs tirzepatide, and GLP-1 side effects.

Making an Informed Decision

Compounded GLP-1 medications occupy a specific position in the treatment landscape, they are neither equivalent to FDA-approved products nor inherently unsafe. They are a legally recognized category of pharmacy practice that serves a clinical purpose when prescribed responsibly and sourced from quality-focused pharmacies.

The patient's responsibility is to be informed. Understand the regulatory status. Ask about the pharmacy source. Confirm that your provider is conducting a genuine clinical evaluation. Request documentation of product quality. Do not accept equivalence claims that are not supported by evidence.

The provider's responsibility is to prescribe based on clinical judgment, use compliant pharmacy partners, communicate transparently about the product's status, and maintain appropriate monitoring.

When both parties fulfill their roles, compounded GLP-1 therapy can be a reasonable component of a physician-supervised weight management protocol. When either party cuts corners, the risk profile changes substantially.

Explore the Bloom Metabolics GLP-1 program, review membership pricing, or schedule a consultation to discuss whether GLP-1 therapy is appropriate for your situation.

Sources

• FDA – Human Drug Compounding: Guidance, Compliance & Regulatory Information
• FDA – Compounding and the FDA: Questions and Answers (503A vs 503B)
• FDA – Drug Shortages Database
• FDA – Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss
• FDA – Section 503A of the Federal Food, Drug, and Cosmetic Act
• FDA – Section 503B Outsourcing Facilities
• USP – Compounding Standards (USP 795, 797, 800)
• Novo Nordisk – Ozempic Prescribing Information
• Eli Lilly – Mounjaro Prescribing Information

---

Medical Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice and does not establish a patient-provider relationship. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or bioequivalence to any commercially available product. The decision to prescribe compounded medications is made by a licensed physician based on individual clinical evaluation. Individual results vary. Regulatory information in this article reflects the landscape as of the publication date and may change. Consult a qualified healthcare provider before making any medical decisions. Content reviewed by Dr. Michael Napolitano, MD.